JNJ's Flatline: Buy Opportunity? I’ve been watching JNJ, and despite its steady dividends, the stock is stuck around $155. Promising drug trials like their psoriasis treatment could boost it if FDA approvals come through. Regulatory risks are a concern, though.Also, keeping an eye on MYNZ, which might soar soon. For now, I’m cautious but optimistic about JNJ’s long-term potential.